Can extended poziotinib use keep cancer in check?

NCT ID NCT03744715

Terminated Disease control Sponsor: Spectrum Pharmaceuticals, Inc Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This trial offers continued treatment with poziotinib for people with non-small cell lung cancer or breast cancer who have already benefited from the drug in a previous study. The goal is to monitor safety and see how long the cancer remains controlled with extended use. Only patients whose doctors believe they are still gaining clinical benefit can join.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: poziotinib
What this could lead to: If successful, this could provide a way for patients who respond to poziotinib to keep receiving it for longer, potentially extending disease control.
What could go wrong: This is a small, open-label extension study with only 7 participants, so results may not apply broadly. Poziotinib can cause side effects like rash and diarrhea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER NSCLC

Contacts and locations

Locations

Hattiesburg Clinic Hematology Oncology

Hattiesburg, Mississippi, 39401, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone

New York, New York, 10016, United States
Pacific Shores Medical Group

Long Beach, California, 90813, United States
UPMC

Pittsburgh, Pennsylvania, 15232, United States
UT MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.